A carregar...
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin’s lymphoma, and glioblastoma....
Na minha lista:
| Publicado no: | NPJ Breast Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6570645/ https://ncbi.nlm.nih.gov/pubmed/31240240 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-019-0112-z |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|